NSRX

Nasus Pharma Ltd.

• TipRanks·04/02 02:07

  Nasus Pharma’s CEO Makes Bold Move With Fresh Insider Buy

• Dow Jones·03/26 13:16

  Nasus Pharma Price Target Cut to $18.00/Share From $19.00 by Citizens

• Dow Jones·03/26 13:16

  Nasus Pharma Is Maintained at Market Outperform by Citizens

• TipRanks·03/26 09:55

  Nasus Pharma price target lowered to $18 from $19 at Citizens

• TipRanks·03/25 20:27

  Nasus Pharma Moves Intranasal Epinephrine Toward Pivotal Trial After Positive Phase 2 Results

• TipRanks·03/25 13:37

  Nasus Pharma advances NS002 to pivotal study following Phase 2 results

• Seeking Alpha·03/25 13:17

  Nasus Pharma Ltd. reports FY results

• TipRanks·03/19 13:00

  Nasus Pharma’s NS002 Demonstrates Consistent Early Advantage in Epinephrine Delivery (NYSE: NSRX)

• TipRanks·03/16 13:00

  Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform

• TipRanks·03/16 12:48

  Nasus Pharma’s NS002 Outperforms EpiPen in Phase 2 Anaphylaxis Study, Pivotal Trial Planned for Late 2026

• TipRanks·03/16 11:36

  Nasus Pharma announces topline data from Phase 2 clinical study of NS002

• TipRanks·03/06 21:29

  Nasus Pharma Shareholders Approve Capital Increase and Amended Articles at March 5 Meeting

• TipRanks·03/04 13:31

  Nasus Pharma Moves March 5 Shareholder Meeting to Virtual-Only Format Amid Israel Security Situation

• TipRanks·03/02 22:35

  Nasus Pharma files to sell 5.39M ordinary shares for holders

• TipRanks·03/02 14:30

  Nasus Approaches Key Data Readout That Could Reshape the Multi Billion Dollar Epinephrine Market (NYSE: NSRX)